Foresite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, closed its fourth and largest fund, with $668m in capital commitments.
Limited partners in Fund IV include new investors as well as a significant representation of existing investors, including university endowments, pension funds, insurance companies and foundations.
Led by founder and CEO Dr. Jim Tananbaum, Dr. Vik Bajaj, Matt Buten, Dorothy Margolskee, Dennis Ryan, and Brett Zbar, Foresite Capital Foresite Capital is a multi-stage healthcare and life sciences investment firm that has invested in both private and public companies that develop innovative therapeutics, discovery and data science tools, and new approaches to clinical care to address significant unmet patient needs.
The firm, which has $2 billion under management, takes a collaborative approach to investing with its portfolio companies by providing a multidisciplinary team of scientists, engineers, analysts, and clinicians who understand the unique business models in healthcare in addition to capital.
The portfolio include 10x Genomics, Inc., Intarcia Therapeutics, Inc., and Aerie Pharmaceuticals, Inc.
Foresite Capital also has an office in New York.